Platelets have a role in vascular complications of COVID-19-related viral coagulopathy.
Although immune-induced thrombocytopenia has been described mostly in moderate-to-severe
COVID-19, the prognostic role of platelet count in COVID-19 is still controversial.
Pseudothrombocytopenia has been reported to represent COVID-19-associated coagulopathy
in critical illness, and transient EDTA-dependent pseudothrombocytopenia lasting less
than 3 weeks was described in a patient with severe acute COVID-19 pneumonia. In our
case study, EDTA-induced pseudothrombocytopenia was still present at 9 months after
an initial SARS-CoV-2 virus infection in an apparently recovered 60 year old man.
The persistence of antinucleocapside and antispike antibodies 9 months after the initial
infection suggests that EDTA-induced pseudothrombocytopenia may be related to anti-SARS-CoV-2
IgG or IgM antibodies. We should acknowledge the possibility that pseudothrombocytopenia
may also appear in some patients after seroconversion after the launch of large-scale
vaccination programs.
